EGFR and non-small cell lung carcinoma: The phase 3 ADAURA trial showed significantly improved disease-free survival with adjuvant osimertinib (89% vs 52%) in resected stage IB to stage IIIA EGFR-mutated NSCLC.14 The phase 3 LAURA trial is currently investigating consolidative osimertinib for patients with unresectable stage III NSCLC after CRT.15 However, use of TKIs in combination with immunotherapy must be pursued carefully given reports of increased toxic effects.16,17,18